SRR8518138
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.420
- TNFA_SIGNALING_VIA_NFKB+0.400
- NOTCH_SIGNALING+0.390
- WNT_BETA_CATENIN_SIGNALING+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- IL6_JAK_STAT3_SIGNALING+0.330
- KRAS_SIGNALING_UP+0.320
- TGF_BETA_SIGNALING+0.320
- INFLAMMATORY_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.290
Top 10 suppressed
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V1-0.450
- FATTY_ACID_METABOLISM-0.420
- OXIDATIVE_PHOSPHORYLATION-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- MTORC1_SIGNALING-0.410
- ADIPOGENESIS-0.380
- PROTEIN_SECRETION-0.380
- MYC_TARGETS_V2-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_03_0038_A2_S89 | — | A | 0.936 |
| 2 | ERR2278881 | — | — | 0.918 |
| 3 | TCGA-A2-A25A-01A-12R-A16F-07 | — | A | 0.915 |
| 4 | TCGA-E2-A1IJ-01A-11R-A144-07 | — | A | 0.913 |
| 5 | TCGA-55-7574-01A-11R-2039-07 | — | cohortMD2 | 0.908 |
| 6 | TCGA-AQ-A7U7-01A-22R-A352-07 | — | D | 0.906 |
| 7 | TCGA-AC-A3W6-01A-12R-A22K-07 | — | A | 0.904 |
| 8 | C3N-03233 | — | cohortA1 | 0.904 |
| 9 | TCGA-60-2715-01A-01R-0851-07 | — | cohortSQ1 | 0.896 |
| 10 | TCGA-DK-AA6S-01A-21R-A39I-07 | — | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.390 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |